Bioventus BVS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $576.3M+1.5% | $568.09M-0.9% | $563.83M+1.6% | $564.14M+5.1% | $567.7M+8.6% | ||
| $180.43M-2.4% | $179.93M-2.8% | $181.8M-0.8% | $182.79M+1.7% | $184.8M+2.6% | ||
| $395.87M+3.4% | $388.16M0.0% | $382.03M+2.7% | $381.35M+6.8% | $382.9M+11.7% | ||
| 68.7%+1.2pp | 68.3%+0.6pp | 67.8%+0.8pp | 67.6%+1.1pp | 67.4%+1.9pp | ||
| $11.57M-19.3% | $12.11M-13.2% | $12.38M-11.2% | $13.3M+1.4% | $14.34M+16.5% | ||
| $318.85M-5.8% | $314.03M-8.7% | $318.14M-5.1% | $320.97M-0.8% | $338.53M+12.2% | ||
| $5.24M-30.0% | $5.73M-25.2% | $6.2M-22.4% | $6.87M-16.7% | $7.49M-11.5% | ||
| —— | —— | —— | —— | -$52K-109% | ||
| $57.52M— | $53.98M— | —— | —— | —— | ||
| 10%— | 9.5%— | —— | —— | —— | ||
| -$23.3M+35.2% | -$26.49M+31.7% | -$30.18M+24.7% | -$33.53M+17.5% | -$35.96M+13.0% | ||
| -$23.88M+31.8% | -$28.27M+23.9% | -$30.68M+21.3% | -$33M+18.8% | -$35.03M+16.0% | ||
| $0+100% | -$81K+72.3% | -$373K+68.8% | -$374K+85.6% | -$373K+89.6% | ||
| $33.64M+167% | $25.71M+149% | $11.51M+119% | $1.58M+102% | -$50.29M-90.3% | ||
| -$899K— | -$1.57M— | —— | —— | —— | ||
| $28.48M+184% | $22.73M+163% | $7.59M+118% | -$731K+98.3% | -$33.87M-54.2% | ||
| 4.9%+10.9pp | 4%+10.3pp | 1.3%+8.9pp | -0.1%+8.1pp | -6%-1.8pp | ||
| $0.41+179% | $0.33+159% | $0.12+118% | -$0.01+98.6% | -$0.52-48.6% | ||
| $0.43+183% | $0.34+161% | $0.12+118% | -$0.01+98.6% | -$0.52-48.6% | ||
| 276.3M+6.3% | 272.3M+5.9% | 267.9M+4.9% | 264.4M+4.5% | 259.9M+3.4% | ||
| 267.3M+2.9% | 266.1M+3.4% | 264M+3.4% | 262.3M+3.7% | 259.9M+3.4% | ||
| -$23.3M+35.2% | -$26.49M+31.7% | -$30.18M+24.7% | -$33.53M+17.5% | -$35.96M+13.0% | ||
| $28.27M+178% | $23.41M+159% | $5.31M+113% | -$1.49M+96.7% | -$36.26M-64.3% | ||
| $0+100% | -$81K+72.3% | -$373K+68.8% | -$374K+85.6% | -$373K+89.6% | ||
| $9K— | -$991K— | -$785K— | $0— | —— | ||
| -$295K+90.1% | $1.81M+143% | -$2.06M-3,129% | -$957K-15.2% | -$2.98M-2,818% | ||
| —— | -$21K-61.5% | -$19K-145% | -$17K-580% | -$15K-645% | ||
| -$250K-127% | -$1.45M-188% | -$176K-116% | $529K+7,657% | $931K+358% | ||
| $576.3M+1.5% | $568.09M-0.9% | $563.83M+1.6% | $564.14M+5.1% | $567.7M+8.6% | ||
| $57.52M+280% | $53.98M+269% | $25.44M+211% | $17.83M+174% | -$32.01M-327% | ||
| $103.87M+489% | $100.99M+474% | $73.16M+174% | $66.43M+146% | $17.63M-73.6% | ||
| $103.87M+489% | $100.99M+474% | $73.16M+174% | $66.43M+146% | $17.63M-73.6% | ||
| 18%+14.9pp | 17.8%+14.7pp | 13%+8.2pp | 11.8%+6.7pp | 3.1%-9.7pp | ||
| $57.52M+280% | $53.98M+269% | $25.44M+211% | $17.83M+174% | -$32.01M-327% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bioventus's revenue?
- Bioventus (BVS) generated $576.3M in revenue over the trailing twelve months, up 1.5% year over year.
- Is Bioventus profitable?
- Bioventus reported $28.5M in net income over the trailing twelve months, a 4.9% net margin.
- What are Bioventus's profit margins?
- Gross margin is 68.7% and operating margin is 10.0%, with a 4.9% net margin.
- What is Bioventus's earnings per share?
- Bioventus's diluted EPS over the trailing twelve months is $0.41.
- Where does Bioventus's income statement data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
